Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Gastroesophageal Junction Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Not applicableLooking for participantsNCT06902545
What this trial is testing

Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc. 377
Testing effectiveness (Phase 2)Study completedNCT03941873
What this trial is testing

Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Who this might be right for
Carcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer
BeiGene 111
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Not applicableUnknownNCT05385809
What this trial is testing

A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer

Who this might be right for
Unresectable Gastric Cancer
Zhejiang Cancer Hospital 100
Testing effectiveness (Phase 2)Study completedNCT00780494
What this trial is testing

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Who this might be right for
Stomach CancerGastric (Stomach) CancerNeoplasm of Cardioesophageal Junction+1 more
Stanford University 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT06251973
What this trial is testing

AgenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Who this might be right for
Metastatic Esophageal CarcinomaAdvanced Unresectable Gastric AdenocarcinomaMetastatic Gastric Cancer+10 more
Memorial Sloan Kettering Cancer Center 20
Testing effectiveness (Phase 2)Study completedNCT03008278
What this trial is testing

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Who this might be right for
Metastatic Esophageal CarcinomaMetastatic Gastric CarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma+10 more
National Cancer Institute (NCI) 51
Testing effectiveness (Phase 2)Study completedNCT00515411
What this trial is testing

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastroesophageal Junction AdenocarcinomaGastric Cancer
Memorial Sloan Kettering Cancer Center 111
Early research (Phase 1)Looking for participantsNCT05107674
What this trial is testing

NX-1607 in Adults With Advanced Malignancies

Who this might be right for
Ovarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer+11 more
Nurix Therapeutics, Inc. 345